Are Medical Stocks Lagging Aurora Cannabis (ACB) This Year?

Group 1 - Aurora Cannabis Inc. is currently ranked 2 (Buy) in the Zacks Rank system, indicating a strong potential for outperforming the market in the next one to three months [3] - The Zacks Consensus Estimate for Aurora Cannabis Inc.'s full-year earnings has increased by 2400% over the past 90 days, reflecting a significant improvement in analyst sentiment [3] - Year-to-date, Aurora Cannabis Inc. has returned approximately 3.8%, outperforming the average return of 3.4% for the Medical sector [4] Group 2 - Aurora Cannabis Inc. belongs to the Medical - Products industry, which consists of 83 individual stocks and is currently ranked 141 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Products industry this year is 6.1%, indicating that Aurora Cannabis Inc. is slightly underperforming its industry [5] - Concentra Group, another Medical stock, has outperformed the sector with a year-to-date return of 5.1% and also holds a Zacks Rank of 2 (Buy) [4][5]